EpiPens – Drugs vs Chairs
slatestarcodex.comI would argue when people claim that they want more regulation, they want more effective regulation for the outcomes that matter to them.
Most people can agree that for a lifesaving product with few to no alternatives that has already well, well passed any period over which the profits have paid back R&D expenditure, there should be some control over how its price can increase over time.
Whether or not this outcome results in strictly more regulation, measured by lines of legislation or individuals with jobs charged enforcing it is irrelevant.
What's with the FDA bashing? The author notes that in the EU there are 8 generic varieties of epinephrine autoinjector on the market, but medicines must go through an approval process in Europe as well.
That's the point.